Overview: HCV NS5A Resistance TestIntroduction: The HCV NS5A Resistance Test identifies hepatitis C genotype 1 NS5A drug resistance mutations to guide treatment, preventing liver damage. Following 2023 AASLD guidelines, it uses PCR for high specificity, aiding in infectious disease screening. This test is critical for optimizing antiviral therapy, managing treatment failures, and improving outcomes in virology for patients with chronic hepatitis C, particularly those with genotype 1 infections.
Other Names: HCV NS5A Resist Assay, Hepatitis C Resistance Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HCV resistance testing began in the 2010s with direct-acting antiviral (DAA) research. PCR-based NS5A genotyping improved in the late 2010s, enhancing treatment optimization.
Purpose: Identifies HCV genotype 1 NS5A resistance mutations, guides antiviral therapy, and monitors resistance in patients to prevent liver damage.
Test Parameters: 1. HCV Genotype 1 NS5A Resistance
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report history of hepatitis C, treatment failures, or symptoms like fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, liver pain, or history of chronic hepatitis C, especially genotype 1. Include current medications, DAA treatment history, and prior treatment failures.
Consent: Written consent required, detailing the tests purpose, resistance implications, and potential need for alternative antiviral therapy.
Procedural Considerations: Uses PCR to identify NS5A resistance mutations (e.g., Y93H). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for patients with prior DAA failure.
Factors Affecting Result Accuracy: Poor RNA quality, low viral load, or contamination can affect results. Antiviral therapy may suppress detectable mutations, requiring careful timing.
Clinical Significance: Identified NS5A resistance mutations guide selection of alternative DAAs, improving treatment success. Negative results may indicate susceptibility to standard therapy.
Specialist Consultation: Consult a hepatologist for result interpretation and antiviral therapy planning.
Additional Supporting Tests: HCV RNA, HCV genotype, or liver function tests to assess treatment response and disease status.
Test Limitations: Limited to genotype 1 infections. Low viral loads may limit mutation detection. Clinical correlation is needed.
References: AASLD Hepatitis C Guidelines, 2023; Hepatology, Ghany MG, 2022.
